{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:55:51Z","timestamp":1758970551676,"version":"3.44.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.clinthera.2014.05.064","type":"journal-article","created":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T08:03:40Z","timestamp":1405929820000},"page":"1064-1071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of Ketoconazole on Lobeglitazone Pharmacokinetics in Korean Volunteers"],"prefix":"10.1016","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct01330563","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eun","family":"Sil Oh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choon","family":"Ok Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki Hyon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youn Nam","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jangik I.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.05.064_bib1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2014.05.064_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0002-9149(02)02555-9","article-title":"Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome","volume":"90","author":"Reusch","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2014.05.064_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2337\/diab.46.1.63","article-title":"Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis Study","volume":"46","author":"Haffner","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2014.05.064_bib4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2337\/diacare.15.8.1075","article-title":"New oral thiazolidinedione antidiabetic agents act as insulin sensitizers","volume":"15","author":"Hofmann","year":"1992","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2014.05.064_bib5","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1074\/jbc.272.12.8071","article-title":"Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPAR\u03b32 versus PPAR\u03b31 and activation with retinoid X receptor agonists and antagonists","volume":"272","author":"Mukherjee","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2014.05.064_bib6","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.2337\/diabetes.53.2007.S43","article-title":"The biology of peroxisome proliferator-activated receptors relationship with lipid metabolism and insulin sensitivity","volume":"53","author":"Ferr\u00e9","year":"2004","journal-title":"Diabetes"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2014.05.064_bib7","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S0021-9150(97)00315-8","article-title":"PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes","volume":"137","author":"Martin","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2014.05.064_bib8","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.bone.2009.06.006","article-title":"Vertebral fractures in males with type 2 diabetes treated with rosiglitazone","volume":"45","author":"Mancini","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2014.05.064_bib9","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.05.064_bib10","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/dc10-1068","article-title":"Risk of bladder cancer among diabetic patients treated with pioglitazone interim report of a longitudinal cohort study","volume":"34","author":"Lewis","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2014.05.064_bib11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejmech.2004.03.001","article-title":"Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione","volume":"39","author":"Kim","year":"2004","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.clinthera.2014.05.064_bib12","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ejmech.2005.03.019","article-title":"Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione","volume":"40","author":"Lee","year":"2005","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.clinthera.2014.05.064_bib13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejmech.2004.03.001","article-title":"Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione","volume":"39","author":"Kim","year":"2004","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.clinthera.2014.05.064_bib14","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1021\/jm0309046","article-title":"Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo","volume":"46","author":"Sauerberg","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2014.05.064_bib15","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.clinthera.2011.09.023","article-title":"Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-\u03b3 agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects","volume":"33","author":"Kim","year":"2011","journal-title":"Clin Ther"},{"year":"2003","series-title":"Actos (pioglitazone hydrochloride) tablets [package insert]","author":"America","key":"10.1016\/j.clinthera.2014.05.064_bib16"},{"key":"10.1016\/j.clinthera.2014.05.064_bib17","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1067\/mcp.2002.129068","article-title":"Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping","volume":"72","author":"Lee","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2014.05.064_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","article-title":"Effects of the antifungal agents on oxidative drug metabolism","volume":"38","author":"Venkatakrishnan","year":"2000","journal-title":"Clin Pharmacokinet"},{"year":"2005","series-title":"Bioequivalence and Statistics in Clinical Pharmacology","author":"Patterson","key":"10.1016\/j.clinthera.2014.05.064_bib19"},{"key":"10.1016\/j.clinthera.2014.05.064_bib20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2337\/diaspect.15.4.240","article-title":"Polypharmacy in elderly patients with diabetes","volume":"15","author":"Good","year":"2002","journal-title":"Diabetes Spectrum"},{"key":"10.1016\/j.clinthera.2014.05.064_bib21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1300\/J027v24n01_07","article-title":"Polypharmacy and possible drug-drug interactions among diabetic patients receiving home health care services","volume":"24","author":"Ibrahim","year":"2005","journal-title":"Home Health Care Serv Q"},{"key":"10.1016\/j.clinthera.2014.05.064_bib22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0091270008331196","article-title":"Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study","volume":"49","author":"Zhao","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2014.05.064_bib23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2125.2004.02161.x","article-title":"Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects","volume":"58","author":"Park","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2014.05.064_bib24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/03602539709037591","article-title":"Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors","volume":"29","author":"Rendic","year":"1997","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.clinthera.2014.05.064_bib25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/AAC.46.1.160-165.2002","article-title":"Interaction of common azole antifungals with P glycoprotein","volume":"46","author":"Wang","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2014.05.064_bib26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0090-9556(24)15271-3","article-title":"Molecular and physical mechanisms of first-pass extraction","volume":"27","author":"Hall","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2014.05.064_bib27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mc.2940130302","article-title":"Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P\u2010glycoprotein: implications for drug delivery and activity in cancer chemotherapy","volume":"13","author":"Wacher","year":"1995","journal-title":"Mol Carinog"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814003555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814003555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:49:31Z","timestamp":1758962971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814003555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0149291814003555"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.05.064","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Ketoconazole on Lobeglitazone Pharmacokinetics in Korean Volunteers","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.05.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier HS Journals, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}